本帖最后由 老马 于 2012-1-13 21:20 编辑
6 L, J( B; f& d9 X5 [1 k/ }$ P! L1 \* d! O) S
爱必妥和阿瓦斯丁的比较$ i) s/ A3 i* s6 W4 m' B
' k/ I* j! g9 Fhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/, _$ ^6 e( R! Y1 k( L" z
4 o. `7 C* a' ]7 k1 q& U+ ?! Z% Y2 t9 _
4 c/ A" X7 I" Ehttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/# n+ ~; k% _/ m/ Z. E' y
==================================================
$ | f0 |3 v: {9 COverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
$ D: q L5 B! ]1 X8 e6 n- LPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
: H4 U2 _# a* F) Q) h- R( ~) CResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.6 ?' c# D: C l& d
|
11011102001537 )
显身卡
/ V2 t% m4 m M0 i7 c" m
